Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.88 |
| ▸ | ESR1 | P03372 | 1/20 | 0.88 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | ACP1 | P24666 | 1/20 | 0.88 |
| ▸ | PDE4A | P27815 | 1/20 | 0.88 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.88 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | YWHAG | P61981 | 1/20 | 0.41 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal Phosphate Anhydrous SCHEMBL23158 | 0.94 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29362986 | 0.94 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL827100 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335524 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL4916108 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL2746592 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29392551 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335516 | 0.92 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL28200961 | 0.89 | ESR1 (0.90) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL10534222 | 0.88 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250143862-A1 | METHODS AND DEVICES FOR PRE-VASCULARIZATION OF IMPLANTATION SITES AND/OR CELL ENCAPSULATION DEVICES | ENCELLIN, INC. | 2025-05-08 | — | — | US | claimed |
| WO-2023107698-A1 | METHODS AND DEVICES FOR PRE-VASCULARIZATION OF IMPLANTATION SITES AND/OR CELL ENCAPSULATION DEVICES | ENCELLIN, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| CN-115494138-A | Novel monomolecular enzyme electrochemical phenol sensor and preparation method and application thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2022-12-20 | — | — | CN | claimed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-3458038-B1 | REDUCED OXYGEN CARRIERS AND THEIR USE FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4648791-A1 | POLYMERIZED HEMOGLOBIN SIZE FRACTIONATED VIA TANGENTIAL FLOW FILTRATION | Ohio State Innovation Foundation (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12433485-B2 | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | DEXCOM, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250243469-A1 | OXYGEN CARRIERS FOR MAINTAINING ORGAN VIABILITY DURING NORMOTHERMIC PERFUSION | OHIO STATE INNOVATION FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20250169491-A1 | POLYMERIZED HEMOGLOBIN SIZE FRACTIONATED VIA TANGENTIAL FLOW FILTRATION WITH LOW AUTO OXIDATION RATES | OHIO STATE INNOVATION FOUNDATION | 2025-05-29 | — | — | US | disclosed |
| US-20250143862-A1 | METHODS AND DEVICES FOR PRE-VASCULARIZATION OF IMPLANTATION SITES AND/OR CELL ENCAPSULATION DEVICES | ENCELLIN, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| US-11439611-B2 | Administration of serine protease inhibitors to the stomach | Leading BioSciences, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11426427-B2 | Isotonic crystalloid aqueous solution | Duque, Lara Oller (ES) | 2022-08-30 | — | — | US | disclosed |
| US-20220228120-A1 | Cardiomyocyte Compositions and Use Thereof | UNIVERSITY HEALTH NETWORK (CA) | 2022-07-21 | — | — | US | disclosed |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-14 | — | — | US | disclosed |
| EP-3193863-B1 | SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | UNIV CAPE TOWN (ZA) | 2022-07-13 | — | — | EP | disclosed |
| CN-111217904-B | Preparation method of polymerized hemoglobin with low high polymer content | 润方（北京）生物医药研究院有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3752594-B1 | BIOCOMPATIBLE THREE-DIMENSIONAL NETWORK AND USE THEREOF AS CELL SUPPORT | UNIV MONTPELLIER (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-20220095607-A1 | PRESERVATION OF VASCULARIZED COMPOSITE ALLOGRAFTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-31 | — | — | US | disclosed |
| EP-3972646-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220228120-A1 | Cardiomyocyte Compositions and Use Thereof | TNNI3, TNNT2, MYLK2 | P2RX2 3909/4885ESR1 3424/4885PTGS1 4638/4885 |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | HBG1, HBG2, LPO | P2RX2 3555/4885ESR1 4426/4885PTGS1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.